Autopsy report · NCT02848001

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

“Trial terminated because of lack of efficacy in the short term acute phase.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 7 years 5 months before it stopped.
• 101 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Celgene

Sponsor type

Industry

Conditions

Leukemia, Myeloid, Acute; Myelodysplastic Syndromes

Interventions

CC-90009

Participants

101

Sites

20

Countries

Canada, France, Norway, Spain, United Kingdom, United States

Trials that died the same way

• Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
  “Trial terminated due to focus of primary therapeutic areas.” (79% match in meaning)
• A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
  “The decision was made to prematurely discontinue this trial due to lack of efficacy.” (79% match in meaning)
• Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
  “The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and no safety concerns.” (75% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (75% match in meaning)
• Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
  “Study was terminated early due to a lack of improved efficacy.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.